VYNE
NASDAQ · Pharmaceuticals
Vyne Therapeutics Inc
$0.64
+0.00 (+0.71%)
Financial Highlights (FY 2026)
Revenue
463.1K
Net Income
-21,559,786
Gross Margin
93.4%
Profit Margin
-4,646.1%
Rev Growth
+5.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.4% | 93.4% | 36.5% | 36.5% |
| Operating Margin | -5,219.1% | -4,697.2% | 24.1% | 26.2% |
| Profit Margin | -4,646.1% | -4,413.8% | 22.3% | 17.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 463.1K | 437.3K | 2.72M | 3.05M |
| Gross Profit | 432.4K | 408.3K | 990.9K | 1.11M |
| Operating Income | -24,169,170 | -20,540,371 | 655.4K | 797.6K |
| Net Income | -21,559,786 | -18,322,764 | 604.8K | 522.0K |
| Gross Margin | 93.4% | 93.4% | 36.5% | 36.5% |
| Operating Margin | -5,219.1% | -4,697.2% | 24.1% | 26.2% |
| Profit Margin | -4,646.1% | -4,413.8% | 22.3% | 17.1% |
| Rev Growth | +5.9% | +5.9% | -5.6% | +23.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 5.81M | 7.24M |
| Total Equity | — | — | 10.77M | 11.64M |
| D/E Ratio | — | — | 0.54 | 0.62 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -21,744,326 | -19,506,241 | 831.2K | 1.01M |
| Free Cash Flow | — | — | 485.0K | 536.6K |